Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. The Company's initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on Company's proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. The Company may occasionally disseminate material, nonpublic information on the Company's website.
Company profile
Ticker
AGRX
Exchange
Website
CEO
Alfred Altomari
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
AGRX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2022 FY
Annual report
22 Mar 23
8-K
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
22 Mar 23
8-K
Departure of Directors or Certain Officers
14 Mar 23
8-K
Agile Therapeutics Granted 180-DAY Extension by Nasdaq to Meet the Minimum Bid Price Requirement
27 Feb 23
DEF 14A
Definitive proxy
9 Feb 23
8-A12G
Registration of securities
26 Jan 23
8-K
Agile Therapeutics Announces Distribution of Series C Preferred Stock to Its Holders of Common Stock
26 Jan 23
PRE 14A
Preliminary proxy
26 Jan 23
8-K
Results of Operations and Financial Condition
9 Jan 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
Transcripts
AGRX
Earnings call transcript
2022 Q3
8 Nov 22
AGRX
Earnings call transcript
2022 Q2
11 Aug 22
AGRX
Earnings call transcript
2022 Q1
13 May 22
AGRX
Earnings call transcript
2021 Q4
30 Mar 22
AGRX
Earnings call transcript
2021 Q3
3 Nov 21
AGRX
Earnings call transcript
2021 Q2
27 Jul 21
AGRX
Earnings call transcript
2021 Q1
5 May 21
AGRX
Earnings call transcript
2020 Q4
2 Mar 21
AGRX
Earnings call transcript
2020 Q3
12 Nov 20
AGRX
Earnings call transcript
2020 Q2
11 Aug 20
Latest ownership filings
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 23
SC 13G/A
Lind Global Fund II LP
13 Feb 23
SC 13G/A
INTRACOASTAL CAPITAL, LLC
8 Feb 23
4
Amy Welsh
14 Nov 22
4
Jason Butch
14 Nov 22
4
Paul Korner
14 Nov 22
4
ALFRED ALTOMARI
14 Nov 22
4
Robert G Conway
14 Nov 22
4
Geoffrey Gilmore
14 Nov 22
3
Amy Welsh
9 Nov 22
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 5.25 mm | 5.25 mm | 5.25 mm | 5.25 mm | 5.25 mm | 5.25 mm |
| Cash burn (monthly) | 299.67 k | 1.16 mm | 2.29 mm | 4.38 mm | 519.67 k | 3.00 mm |
| Cash used (since last report) | 868.70 k | 3.36 mm | 6.65 mm | 12.70 mm | 1.51 mm | 8.68 mm |
| Cash remaining | 4.38 mm | 1.89 mm | -1.40 mm | -7.45 mm | 3.74 mm | -3.44 mm |
| Runway (months of cash) | 14.6 | 1.6 | -0.6 | -1.7 | 7.2 | -1.1 |
Institutional ownership, Q3 2022
22.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 28 |
| Opened positions | 10 |
| Closed positions | 3 |
| Increased positions | 8 |
| Reduced positions | 5 |
| 13F shares | Current |
|---|---|
| Total value | 5.08 mm |
| Total shares | 8.93 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Intracoastal Capital | 3.43 mm | $2.20 mm |
| Lind Global Fund II | 3.25 mm | $2.22 mm |
| Perceptive Advisors | 532.36 k | $158.00 k |
| LPL Financial | 411.51 k | $122.00 k |
| BLK Blackrock | 303.80 k | $91.00 k |
| Geode Capital Management | 216.67 k | $64.00 k |
| Millennium Management | 186.86 k | $55.00 k |
| Renaissance Technologies | 151.72 k | $45.00 k |
| IVSBF Investor AB | 87.75 k | $26.00 k |
| Advisory Services Network | 76.00 k | $23.00 k |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Nov 22 | Gilmore Geoffrey | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.2 | 10,000 | 2.00 k | 10,000 |
| 9 Nov 22 | Robert G Conway | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.2 | 10,000 | 2.00 k | 10,000 |
| 9 Nov 22 | Altomari Alfred | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.2 | 30,000 | 6.00 k | 30,000 |
| 9 Nov 22 | Jason Butch | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.2 | 6,000 | 1.20 k | 6,000 |
| 9 Nov 22 | Amy Welsh | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 0.2 | 10,000 | 2.00 k | 10,000 |
News
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
23 Mar 23
Agile Therapeutics's Return On Capital Employed Insights
23 Mar 23
Why Agile Therapeutics Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
23 Mar 23
Agile Therapeutics Q4 EPS $(0.18) Beats $(0.23) Estimate, Sales $4.00M Beat $3.08M Estimate
22 Mar 23
Earnings Scheduled For March 22, 2023
22 Mar 23
Press releases
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
22 Mar 23
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
21 Mar 23
Corium Pharma Solutions Names Two Industry Veterans to its Executive Team
9 Feb 23
Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
1 Feb 23
Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
26 Jan 23